Publications


A Behavior-Modification, Clinical-Grade Mobile Application to Improve Breast Cancer Survivors' Accountability and Health Outcomes;
Stubbins, R, He, T, Yu, X, Puppala, M, Ezeana, CF, Chen, S, Valdivia y Alvarado, M, Ensor, J, Rodriguez, A, Niravath, P, Chang, J, Wong, STC & Patel, T 2018, JCO Clinical Cancer Informatics, no. 2, pp. 1-11. https://doi.org/10.1200/CCI.18.00054

Systems biology-based drug repositioning identifies digoxin as a potential therapy for groups 3 and 4 medulloblastoma;
Huang, L, Injac, SG, Cui, K, Braun, F, Lin, Q, Du, Y, Zhang, H, Kogiso, M, Lindsay, H, Zhao, S, Baxter, P, Adekunle, A, Man, TK, Zhao, H, Li, XN, Lau, CC & Wong, ST 2018, Science Translational Medicine, vol. 10, no. 464, eaat0150. https://doi.org/10.1126/scitranslmed.aat0150

Dual suppressive effect of miR-34A on the FOXM1/EEF2-kinase axis regulates triple-negative breast cancer growth and invasion;
Bayraktar, R, Ivan, C, Bayraktar, E, Kanlikilicer, P, Kabil, NN, Kahraman, N, Mokhlis, HA, Karakas, D, Rodriguez-Aguayo, C, Arslan, A, Sheng, J, Wong, S, Lopez-Berestein, G, Calin, GA & Ozpolat, B 2018, Clinical Cancer Research, vol. 24, no. 17, pp. 4225-4241. https://doi.org/10.1158/1078-0432.CCR-17-1959

Sustained adrenergic signaling promotes intratumoral innervation through BDNF induction;
Allen, JK, Armaiz-Pena, GN, Nagaraja, AS, Sadaoui, NC, Ortiz, T, Dood, R, Ozcan, M, Herder, DM, Haemmerle, M, Gharpure, KM, Rupaimoole, R, Previs, RA, Wu, SY, Pradeep, S, Xu, X, Han, HD, Zand, B, Dalton, HJ, Taylor, M, Hu, W, Bottsford-Miller, J, Moreno-Smith, M, Kang, Y, Mangala, LS, Rodriguez-Aguayo, C, Sehgal, V, Spaeth, EL, Ram, PT, Wong, STC, Marini, FC, Lopez-Berestein, G, Cole, SW, Lutgendorf, SK, De Biasi, M & Sood, AK 2018, Cancer Research, vol. 78, no. 12, pp. 3233-3242. https://doi.org/10.1158/0008-5472.CAN-16-1701c

Two birds, one stone: Hesperetin alleviates chemotherapyinduced diarrhea and potentiates tumor inhibition;
Yu, Y, Kong, R, Cao, H, Yin, Z, Liu, J, Nan, X, Phan, AT, Ding, T, Zhao, H & Wong, STC 2018, Oncotarget, vol. 9, no. 46, pp. 27958-27973. https://doi.org/10.18632/oncotarget.24563

Is pathology prepared for the adoption of artificial intelligence?;
Wong, ST 2018, Cancer Cytopathology, vol. 126, no. 6, pp. 373-375. https://doi.org/10.1002/cncy.21994

Systematic Identification of Druggable Epithelial-Stromal Crosstalk Signaling Networks in Ovarian Cancer;
Yeung, T-L, Sheng, J, Leung, CS, Li, F, Kim, J, Ho, SY, Matzuk, MM, Lu, KH, Wong, STC & Mok, SC 2018, Journal of the National Cancer Institute. https://doi.org/10.1093/jnci/djy097

Evaluating the Therapeutic Relevance of Targeting TWIST1 Through Loss of Function Studies in Human Glioblastoma: AANS Annual Scientific Meeting, New Orleans, Louisiana, April 28-May 2, 2018;
Mikheev, A, Mikheeva, SA, Severs, LJ, Funk, CC, Huang, L, Mcfaline-Figueroa, JL, Schwensen, J, Trapnell, C, Price, ND, Wong, ST & Rostomily, RC 2018, .

Targeting brain-adaptive cancer stem cells prohibits brain metastatic colonization of triple-negative breast cancer;
Ren, D, Zhu, X, Kong, R, Zhao, Z, Sheng, J, Wang, J, Xu, X, Liu, J, Cui, K, Zhang, XHF, Zhao, H & Wong, STC 2018, Cancer Research, vol. 78, no. 8, pp. 2052-2064. https://doi.org/10.1158/0008-5472.CAN-17-2994